Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,150)

Items 401–500 of 12,150

1. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
   Lorraine Lucille Lipscombe, Gillian L. Booth, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R. Shah, Scot H. Simpson · 2018 · Canadian Journal of Diabetes
2. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
   Christoph Maack, Michael Lehrke, Johannes Backs, Frank R. Heinzel, Jean‐Sébastien Hulot, Nikolaus Marx, Walter J. Paulus, Patrick Rossignol, Heinrich Taegtmeyer, Johann K Bauersachs et al. · 2018 · European Heart Journal
3. Pharmacological treatment of hyperglycemia in type 2 diabetes
   Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees · 2021 · Journal of Clinical Investigation
4. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
   Fitchett, David, Butler, Javed, van de Borne, Philippe, Zinman, Bernard, Lachin, John M, Wanner, Christoph, Woerle, Hans J, Hantel, Stefan, George, Jyothis T, Johansen, Odd Erik et al. · 2018 · European Heart Journal
5. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
   Annabelle M Warren, Søren Tang Knudsen, Mark E. Cooper · 2019 · Expert Opinion on Therapeutic Targets
6. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
   Jinpeng Li, Haijie Liu, Susumu Takagi, Kyoko Nitta, Munehiro Kitada, Swayam Prakash Srivastava, Yuta Takagaki, Keizo Kanasaki, Daisuke Koya · 2020 · JCI Insight
7. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure
   Natalie Mordi, Ify R. Mordi, Jagdeep S. Singh, Rory J. McCrimmon, Allan D. Struthers, Chim Choy Lang · 2020 · Circulation
8. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
   Mancini, Sarah J., Boyd, Daria, Katwan, Omar J., Strembitska, Anastasiya, Almabrouk, Tarek A., Kennedy, Simon, Palmer, Timothy M., Salt, Ian P. · 2018 · Scientific Reports
9. Dapagliflozin: A Review in Type 2 Diabetes
   Sohita Dhillon · 2019 · Drugs
10. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
    Cosentino, Francesco, Cannon, Christopher P., Cherney, David Z.I., Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J. et al. · 2020 · Circulation
11. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
    Fadini, Gian Paolo, Bonora, Benedetta Maria, Avogaro, Angelo · 2017 · Diabetologia
12. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
    Nicholls, Stephen J., Bhatt, Deepak L, Buse, John B, Prato, Stefano Del, Kahn, Steven E, Lincoff, A Michael, McGuire, Darren K, Nauck, Michael A, Nissen, Steven E, Sattar, Naveed et al. · 2024 · American Heart Journal
13. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics
    Jardine, Meg J., Mahaffey, Kenneth W., Neal, Bruce, Agarwal, Rajiv, Bakris, George L., Brenner, Barry M., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick et al. · 2017 · American Journal of Nephrology
14. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
    Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, Harald Sourij, Steven R. Houser, Markus Wallner · 2018 · Frontiers in Physiology
15. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
    Alexander J M Brown, Stephen J. Gandy, Rory J. McCrimmon, J. Graeme Houston, Allan D. Struthers, Chim Choy Lang · 2020 · European Heart Journal
16. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, Prabhat Jha, Baiju R. Shah · 2022 · Nature Reviews Endocrinology
17. Diabetes Mellitus and Heart Failure
    Lehrke, Michael, Marx, Nikolaus · 2017 · The American Journal of Cardiology
18. SGLT2 Inhibitor–Induced Sympathoinhibition
    Herat, Lakshini Y., Magno, Aaron L., Rudnicka, Caroline, Hricova, Jana, Carnagarin, Revathy, Ward, Natalie C., Arcambal, Angelique, Kiuchi, Marcio G., Head, Geoff A., Schlaich, Markus P. et al. · 2020 · JACC: Basic to Translational Science
19. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Heidi Storgaard, Lise Lotte Gluud, Cathy Bennett, Magnus F.G. Grøndahl, Mikkel Christensen, Filip Krag Knop, Tina Vilsbøll · 2016 · PLoS ONE
20. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
    Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin et al. · 2018 · Clinical Kidney Journal
21. Treatment of Diabetic Kidney Disease: Current and Future
    Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku · 2021 · Diabetes & Metabolism Journal
22. Coronary heart disease risk: Low-density lipoprotein and beyond
    Gabriel E. Shaya, Thorsten Martin Leucker, Steven Richard Jones, Seth Shay Martin, Peter Paul Toth · 2021 · Trends in Cardiovascular Medicine
23. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
    Zelniker, Thomas A., Braunwald, Eugene · 2018 · Journal of the American College of Cardiology
24. Reframing the Association and Significance of Co-Morbidities in Heart Failure
    Filippos K. Triposkiadis, Grigorios Giamouzis, John Parissis, Randall C. Starling, Harisios K Boudoulas, John S. Skoularigis, Javed Butler, Gerasimos S Filippatos · 2016 · European Journal of Heart Failure
25. Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
    Lars Christian Gormsen, Mads Vandsted Svart, Henrik Holm Thomsen, Esben Søndergaard, Mikkel Holm Vendelbo, Nana Louise Christensen, Lars Poulsen Tolbod, Hendrik Johannes Harms, Roni Ranghoej Nielsen, Henrik Wiggers et al. · 2017 · Journal of the American Heart Association
26. Impact of Diabetes Mellitus on Bone Health
    Cliodhna E. Murray, Cynthia M. Coleman · 2019 · International Journal of Molecular Sciences
27. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
    Subodh Verma, Ankit Garg, Andrew Tze-Kay Yan, Anup K. Gupta, Mohammed A. Al-Omran, Andre Sabongui, Hwee Teoh, C. David Mazer, Kim Alexander Connelly · 2016 · Diabetes Care
28. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
    Matthew J. Levine · 2016 · Current Diabetes Reviews
29. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
    Milton Packer · 2017 · Circulation
30. ACC/AHA Versus ESC Guidelines on Heart Failure
    Peter van der Meer, Hanna Kim Gaggin, G. WILLIAM DEC · 2019 · Journal of the American College of Cardiology
31. SGLT2i: beyond the glucose-lowering effect
    Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu · 2020 · Cardiovascular Diabetology
32. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
    Cyrielle Caussy, Adrien Aubin, Rohit Seth Loomba · 2021 · Current Diabetes Reports
33. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies
    Silbert, Richard, Salcido-Montenegro, Alejandro, Rodriguez-Gutierrez, Rene, Katabi, Abdulrahman, McCoy, Rozalina G. · 2018 · Current Diabetes Reports
34. Protective role of melatonin in cardiac ischemia‐reperfusion injury: From pathogenesis to targeted therapy
    Hao Zhou, Qiang Ma, Pingjun Zhu, Jun Tao Ren, Russel Joseph Reiter, Yundai Chen · 2018 · Journal of Pineal Research
35. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.
    Reaven, Peter D., Emanuele, Nicholas V., Wiitala, Wyndy L., Bahn, Gideon D., Reda, Domenic J., McCarren, Madeline, Duckworth, William C., Hayward, Rodney A. · 2019 · New England Journal of Medicine
36. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
    Wataru Shimizu, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano et al. · 2020 · Cardiovascular Diabetology
37. Protective Factors and the Pathogenesis of Complications in Diabetes
    Marc Gregory Yu, Daniel Gordin, Jialin Fu, Kyoungmin Park, Qian Li, George Liang King · 2023 · Endocrine Reviews
38. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes
    Michael James Kraakman, Man K.S. Lee, Annas Al‐Sharea, Dragana Dragoljevic, Tessa J. Barrett, Emilie Montenont, Debapriya Basu, Sarah Elizabeth Heywood, Hélène L. Kammoun, Michelle Flynn et al. · 2017 · Journal of Clinical Investigation
39. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
    Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans‐Ulrich Häring, Norbert Stefan, Andreas Fritsche, Ferruh Artunç · 2019 · Cardiovascular Diabetology
40. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
    Matthews, Vance B., Elliot, Rosemary H., Rudnicka, Caroline, Hricova, Jana, Herat, Lakshini, Schlaich, Markus P. · 2017 · Journal of Hypertension
41. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus
    Halden, Thea Anine Strøm, Kvitne, Kine Eide, Midtvedt, Karsten, Rajakumar, Laavanyaah, Robertsen, Ida, Brox, Jan, Bollerslev, Jens, Hartmann, Anders, Åsberg, Anders, Jenssen, Trond · 2019 · Diabetes Care
42. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
    Marjot, Thomas, Moolla, Ahmad, Cobbold, Jeremy F, Hodson, Leanne, Tomlinson, Jeremy W · 2020 · Endocrine Reviews
43. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
    Hongyu Qiu, Aleksandra Novikov, Volker Vallon · 2017 · Diabetes/Metabolism Research and Reviews
44. Empagliflozin Reduces Ca/Calmodulin-Dependent Kinase II Activity in Isolated Ventricular Cardiomyocytes
    Julian Mustroph, Olivia Wagemann, Charlotte M. Lücht et al. · 2018 · ESC Heart Failure
45. Concept of Extremes in Vascular Aging
    Stéphane Laurent, Pierre Boutouyrie, Pedro Cunha, Patrick J. Lacolley, Peter M. Nilsson · 2019 · Hypertension
46. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo‐Kyung Kim, Seung‐Hwan Lee, Jae‐Seung Yun, Jong Ha Baek, Junghyun Noh, Byung‐Wan Lee, Tae Jung Oh et al. · 2021 · Diabetes & Metabolism Journal
47. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
    DeFronzo, Ralph A, Inzucchi, Silvio, Abdul-Ghani, Muhammad, Nissen, Steven E · 2019 · Diabetes and Vascular Disease Research
48. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
    Jacob Allen Udell, Žhong Yuan, Toni M. Rush, Nicholas Sicignano, Michael S. Galitz, Norman R Rosenthal · 2017 · Circulation
49. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
    Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G.C. Van Spall, Jozine M. ter Maaten, Kevin Damman · 2022 · Circulation
50. Empagliflozin directly improves diastolic function in human heart failure
    Pabel, Steffen, Wagner, Stefan, Bollenberg, Hannah, Bengel, Philipp, Kovács, Árpád, Schach, Christian, Tirilomis, Petros, Mustroph, Julian, Renner, André, Gummert, Jan et al. · 2018 · European Journal of Heart Failure
51. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
    Donnan, Jennifer R, Grandy, Catherine A, Chibrikov, Eugene, Marra, Carlo A, Aubrey-Bassler, Kris, Johnston, Karissa, Swab, Michelle, Hache, Jenna, Curnew, Daniel, Nguyen, Hai et al. · 2019 · BMJ Open
52. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017
    Theodore H. Wein, M. Patrice Lindsay, Robert Côté, Norine C. Foley, Joseph Berlingieri, Sanjit Kaur Bhogal, Aline Bourgoin, Brian H Buck, Jafna L. Cox, Dion Davidson et al. · 2017 · International Journal of Stroke
53. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches
    Philip Düsing, Andreas Zietzer, Philip Roger Goody, Mohammed Rabiul Hosen, Christian Kurts, Georg Nickenig, Felix Jansen · 2021 · Journal of Molecular Medicine
54. 9. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2017 · Diabetes Care
55. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
    Birkeland, Kåre I., Bodegard, Johan, Eriksson, Jan W., Norhammar, Anna, Haller, Hermann, Linssen, Gerard C.M., Banerjee, Amitava, Thuresson, Marcus, Okami, Suguru, Garal‐Pantaler, Elena et al. · 2020 · Diabetes, Obesity and Metabolism
56. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
    Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z.I. Cherney · 2022 · Kidney International Reports
57. The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics
    McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S. et al. · 2019 · European Journal of Heart Failure
58. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
    Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, Mark H.H. Kramer, Max Nieuwdorp, Daniël H. van Raalte · 2017 · Clinical Journal of the American Society of Nephrology
59. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth
    Philip Scott Zeitler, Silva A Arslanian, Junfen Fu, Orit Pinhas‐Hamiel, Thomas Reinehr, Nikhil Tandon, Tatsuhiko Urakami, Jencia Wong, David M. Maahs · 2018 · Pediatric Diabetes
60. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study
    Patorno, Elisabetta, Pawar, Ajinkya, Franklin, Jessica M., Najafzadeh, Mehdi, Déruaz-Luyet, Anouk, Brodovicz, Kimberly G., Sambevski, Steven, Bessette, Lily G., Santiago Ortiz, Adrian J., Kulldorff, Martin et al. · 2019 · Circulation
61. Disorders of lipid metabolism. Clinical Guidelines 2023
    Ежов Марат Владиславович, Valery V. Kukharchuk, И. В. Сергиенко, Asiiat S. Alieva, Mikhail Borisovich Antsiferov, Alexey A. Ansheles, Gurami G. Arabidze, Aronov Dm, G. P. Arutyunov, Н. М. Ахмеджанов et al. · 2023 · Russian Journal of Cardiology
62. Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: Amultinational observational study
    Persson, Frederik, Nyström, Thomas, Jørgensen, Marit E., Carstensen, Bendix, Gulseth, Hanne L., Thuresson, Marcus, Fenici, Peter, Nathanson, David, Eriksson, Jan W., Norhammar, Anna et al. · 2018 · Diabetes, Obesity and Metabolism
63. 12. Older Adults: Standards of Medical Care in Diabetes—2021
    American Diabetes Association · 2020 · Diabetes Care
64. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
    Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, Antonella Pansini, Angela Lombardi, Salvatore Frullone, Gaetano Santulli · 2022 · Hypertension
65. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
    Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn Matthew Chertow, Ricardo Correa‐Rotter, Tom Greene, Fan Fan Hou, Magnus Lindberg, John J.V. McMurray, Peter R Rossing, Robert D. Toto et al. · 2019 · Nephrology Dialysis Transplantation
66. Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
    Mohamad Arow, Maayan Waldman, Dor Yadin, Vadim Nudelman, Asher Shainberg, Nader G. Abraham, Dov Freimark, Ran Kornowski, Dan J. Aravot, Edith Hochhauser et al. · 2020 · Cardiovascular Diabetology
67. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
    Mee Kyoung Kim, Seung‐Hyun Ko, Bo‐Yeon Kim, Eun Seok Kang, Junghyun Noh, Soo‐Kyung Kim, Seok-O Park, Kyu Yeon Hur, Suk Chon, Min Kyong Moon et al. · 2019 · Diabetes & Metabolism Journal
68. Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications
    Arpeeta Sharma, Mitchel Tate, Geetha Mathew, James Edward Vince, Rebecca Helen Ritchie, Judy B. de Haan · 2018 · Frontiers in Physiology
69. Cardiovascular disease in diabetes, beyond glucose
    Robert H. Eckel, Karin Bornfeldt, Ira J. Goldberg · 2021 · Cell Metabolism
70. Biological Phenotypes of Heart Failure With Preserved Ejection Fraction
    Gavin A. Lewis, Erik B. Schelbert, Simon G. Williams, Colin Cunnington, Fozia Zahir Ahmed, Theresa A. McDonagh, Chris Miller · 2017 · Journal of the American College of Cardiology
71. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability
    Esther Díaz‐Rodriguez, Rosa María Agra, Ángel Luis Fernández, Belén Adrio, Tomás García‐Caballero, José Ramón González‐Juanatey, Sonia Eirás · 2017 · Cardiovascular Research
72. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
    Luis Miguel Ruilope, Rajiv Agarwal, Stefan D. Anker, George L. Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt et al. · 2019 · American Journal of Nephrology
73. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
    Gilson Costa Fernandes, Amanda Dantas Ferreira Fernandes, Rhanderson N. Cardoso, Jorge Peñalver, Leonardo Knijnik, Raul David Mitrani, Robert J. Myerburg, Jeffrey J. Goldberger · 2021 · Heart Rhythm
74. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Alexander Yu. Mayorov, Natalia G. Mokrysheva, Elena Nikolaevna Andreeva, Olga B. Bezlepkina, Valentina Aleksandrovna Peterkova, Ekaterina Viktorovna Artemova, Petr S. Bardiugov, Diana Dzhemalovna Beshlieva et al. · 2023 · Diabetes Mellitus
75. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
    Kraus, Bettina J., Weir, Matthew R., Bakris, George L., Mattheus, Michaela, Cherney, David Z.I., Sattar, Naveed, Heerspink, Hiddo J.L., Ritter, Ivana, von Eynatten, Maximilian, Zinman, Bernard et al. · 2021 · Kidney International
76. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
    Giuseppe Daniele, Juan Xiong, Carolina Solis‐Herrera, Aurora Merovci, Roy Eldor, Devjit Tripathy, Ralph Anthony DeFronzo, Luke Norton, Muhammad A Abdul‐Ghani · 2016 · Diabetes Care
77. Insights into Glomerular Filtration and Albuminuria
    Thomas R. Benzing, David J. Salant · 2021 · New England Journal of Medicine
78. Diabetic fibrosis
    Izabela Tuleta, Nikolaos Georgios Frangogiannis · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
79. SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials
    Tang, Huilin, Dai, Qi, Shi, Weilong, Zhai, Suodi, Song, Yiqing, Han, Jiali · 2017 · Diabetologia
80. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
    Jingjing Tian, Mingjun Zhang, Mengying Suo, Dian Liu, Xuyang Wang, Ming Rong Liu, Jinyu Pan, Tao Jin, Fengshuang An · 2021 · Journal of Cellular and Molecular Medicine
81. Hypertension management in patients with cardiovascular comorbidities
    Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus Peter Schlaich, Koon Kang Teo et al. · 2022 · European Heart Journal
82. Modelling diabetic nephropathy in mice
    Kengo Azushima, Susan B. Gurley, Thomas M. Coffman · 2017 · Nature Reviews Nephrology
83. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
    Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina · 2020 · Diabetes, Obesity and Metabolism
84. 13. Older Adults: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
85. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME Trial
    Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian et al. · 2018 · Journal of the American Society of Nephrology
86. A role for tubular Na+/H+exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
    Onishi, Akira, Fu, Yiling, Patel, Rohit, Darshi, Manjula, Crespo-Masip, Maria, Huang, Winnie, Song, Panai, Freeman, Brent, Kim, Young Chul, Soleimani, Manoocher et al. · 2020 · American Journal of Physiology-Renal Physiology
87. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
    Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, Emanuele Gallinoro, Arturo Cesaro, Felice Gragnano, Celestino Sardu, Niya Boykova Mileva, Alberto Foà, Matteo Armillotta et al. · 2022 · Cardiovascular Diabetology
88. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Alexander Yu. Mayorov, Natalya G. Mokrysheva, Ol'ga Konstantinovna Vikulova, Gagik Radikovich Galstyan, Тамара Леонидовна Кураева, Valentina Aleksandrovna Peterkova, Olga Mikhailovna Smirnova, Elena Georgievna Starostina et al. · 2022 · Diabetes Mellitus
89. Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes
    Deborah E. Sellmeyer, Roberto Civitelli, Lorenz Christian Hofbauer, Sundeep Khosla, Beata Lecka‐Czernik, Ann V. Schwartz · 2016 · Diabetes
90. Heart Failure in Patients with Diabetes Mellitus
    Giuseppe M.C. Rosano, Cristiana Vitale, Petar M Seferovic · 2017 · Cardiac failure review
91. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
    James L. Januzzi, Javed Butler, Petr Jarolı́m, Naveed A. Sattar, Ujjwala Vijapurkar, Mehul G. Desai, Michael J. Davies · 2017 · Journal of the American College of Cardiology
92. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
    Yifan Zhang, Daisuke Nakano, Yu Guan, Hirofumi Hitomi, Akiyoshi Uemura, Tsutomu Masaki, Hideki Kobara, Takeshi Sugaya, Akira Nishiyama · 2018 · Kidney International
93. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
    Newman, Jonathan D., Schwartzbard, Arthur Z., Weintraub, Howard S., Goldberg, Ira J., Berger, Jeffrey S. · 2017 · Journal of the American College of Cardiology
94. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
    Kristensen, Søren L., Mogensen, Ulrik M., Jhund, Pardeep S., Petrie, Mark C., Preiss, David, Win, Sithu, Køber, Lars, McKelvie, Robert S., Zile, Michael R., Anand, Inder S. et al. · 2017 · Circulation
95. Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
    William L. Baker, Leo Francis Buckley, Michael S. Kelly, John D. Bucheit, Eric D. Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L. Dixon · 2017 · Journal of the American Heart Association
96. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
    Pantelis A. Sarafidis, Charles Joseph Ferro, Enrique Morales, Alberto Ortíz, Jolanta Małyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, José Manuel Valdivielso, Denis P. Fouque et al. · 2019 · Nephrology Dialysis Transplantation
97. The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
    Hsiang‐Chun Lee, Yi-Lin Shiou, Shih‐Jie Jhuo, Chia-Yuan Chang, Po‐Len Liu, Wun-Jyun Jhuang, Zen‐Kong Dai, Wei‐Yu Chen, Yun-Fang Chen, An‐Sheng Lee · 2019 · Cardiovascular Diabetology
98. Metabolomics and Proteomics in Type 2 Diabetes
    Zsu‐Zsu Chen, Robert Edgardo Gerszten · 2020 · Circulation Research
99. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
    Cusi, Kenneth, Bril, Fernando, Barb, Diana, Polidori, David, Sha, Sue, Ghosh, Atalanta, Farrell, Kristin, Sunny, Nishanth E., Kalavalapalli, Srilaxmi, Pettus, Jeremy et al. · 2019 · Diabetes, Obesity and Metabolism
100. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies
     Wilfried Müllens, Frederik Hendrik Verbrugge, Petra Nijst, W.H. Wilson Tang · 2017 · European Heart Journal